Infusion of modified donor immune cells after stem cell transplant for blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) following the transplantation of TCRα/β/CD19 depleted peripheral blood stem cells in patients with hematologic malignancies. Participants will undergo a reduced intensity conditioning regimen before receiving the stem cell infusion. If no severe graft-versus-host disease (GVHD) occurs, patients will receive the DLI on Day 30 post-transplant. The trial includes a dose-finding phase (Phase I) to determine the maximum tolerated dose, which will then be used in the confirmatory Phase II part of the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Adult and pediatric patients with hematological malignancies in complete remission (CR), partial remission (PR) or with stable disease

* Acute myeloid leukemia (AML):

  * Patients with high-risk AML in first complete remission (CR1)
  * Patients with relapsed or primary therapy-refractory AML
* Acute lymphoid leukemia (ALL):

  * Patients with high-risk ALL in CR1
  * Patients with relapsed or primary refractory ALL
* Hodgkin's disease: Patients with relapsed or primary refractory Hodgkin's disease
* Non-Hodgkin's lymphoma: Patients with relapsed or primary refractory Non- Hodgkin's lymphoma
* Myelodysplastic Syndrome (MDS)/ Myeloproliferative Syndrome (MPS):

  °Patients with refractory MDS/MPS
* Multiple myeloma (MM): Patients with relapsed or refractory multiple myeloma

Exclusion Criteria:

* Age \>65 years or \<8 weeks
* Patients with progressive disease prior hematopoietic cell transplantation (HCT)
* \<3 months after preceding HCT
* Treatment with T-cell or Interleukin-2 (IL-2) targeted medication (e.g. alemtuzumab, basiliximab) within 60 days prior to study product infusion
* Treatment with prednisolone at \>2 mg/kg/day (or equivalent dosing of alternative glucocorticosteroids) at time of study product infusion.
* Known allergy/hypersensitivity to any component of the study product
* Treatment with another investigational drug within one month before inclusion
* History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukoencephalopathy, active Central Nervous System (CNS) infection) Note: For patients with heavy pretreatment with irradiation or intrathecal chemotherapy pre-transplant CNS MRI and neurological consultation are mandatory.
* Fungal infections with radiological and clinical progression
* Liver function abnormalities with bilirubin \>2 mg/dL and elevation of transaminases higher than 400 U/L
* Chronic active viral hepatitis
* Ejection fraction \<40% or Shortening fraction \<20% on echocardiography. Patients with \> grade II hypertension by Common Toxicity Criteria (CTC)
* Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard
* Respiratory failure necessitating supplemental oxygen
* HIV infection
* Female patients who are pregnant or breast feeding, or adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter Note: Women of childbearing potential must have a negative serum pregnancy test at study entry.
* Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study
* Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
* Patients unwilling or unable to comply with the protocol or unable to give informed consent

Where it's running

• University Children's Hospital University Clinic Tuebingen
  Tübingen, Germany Recruiting
• University Hospital Tuebingen, Department of Hematology, Oncology, Immunology and Rheumatology
  Tübingen, Germany Recruiting

Study contacts

• Study coordinator: Wolfgang Bethge, MD, PhD
• Email: wolfgang.bethge@med.uni-tuebingen.de
• Phone: +49 7071 29-83176

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant

  This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, SH · NCT07662369

• Identifying biomarkers for CAR-T cell therapy in cancer patients

  This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.

  Recruiting University Hospital, Lille · Lille and 1 other locations · NCT07609485

• QH101 Vδ2 T-cell therapy for adults with relapsed or advanced malignant tumors

  This study will try QH101, an off-the-shelf Vδ2 T-cell therapy, in adults with relapsed or advanced blood cancers or solid tumors to see if it is safe and helps fight tumors.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07570563

• Short versus long maribavir treatment after allogeneic stem cell transplant

  This trial tests whether a shorter or longer course of maribavir helps adults with refractory CMV infection after their first allogeneic stem cell transplant.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07511127

• Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients

  This study tests whether a self-report iPad tool called DCog Short can help identify neurotoxicity in people receiving CAR-T cell therapy.

  Recruiting Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07403812

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.